Research
Hormonal
Once-weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces body weight, BMI, and waist circumference in adults with obesity or overweight compared to placebo, with effects demonstrating a dose-response relationship.
For adults with obesity or overweight, once-weekly semaglutide (titrated up to 2.4 mg) combined with lifestyle changes is a highly effective medical intervention for significant weight loss, outperforming lifestyle changes alone. While gastrointestinal side effects like nausea are common, they are usually manageable and do not typically lead to stopping treatment.
StrongSupportsVERY_HIGH confidence
Compared with placebo, semaglutide was more effective in reducing body weight (WMD: 5.52 kg, 95% CI:-7.35kg, -5.78kg, P <0.00001) and percentage of body weight by 10.88% (95% CI:-12.98%, -8.79%).
Why this rating
Systematic review and meta-analysis of 9 RCTs with 5324 patients.
Source
Effects of once-weekly semaglutide in obese/overweight patients: A systematic review and meta-analysis
Mengjun Wang et al. · Research Square · 2022
Meta-analysis · 9 studies
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →